Trial Profile
A Pilot Open-Label Study to Evaluate the Safety and Observe the Effectiveness of 16 Weeks of Alefacept in Palmar Plantar Pustulosis (IST 92)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alefacept (Primary)
- Indications Palmoplantar pustulosis
- Focus Therapeutic Use
- 09 Jun 2015 New trial record